Immunotherapy for childhood leukemia and solid tumors using dendritic cells
Immunotherapy for childhood leukemia and solid tumors using dendritic cells
批准号:
18591191
负责人:
MATSUZAKI Akinobu
金额:
$2.49万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2006
资助国家:
日本
项目状态:
已结题
起止时间:
2006 至 2007
中文摘要
点击翻译按钮获取中文摘要
英文摘要
(1)Generation of leukemia cell-derived dendritic cells (DCs): In order to establish the effective immunotherapy using DCs, DCs were generated directly from leukemia cells. When primary leukemia blasts were cultured in the presence of GM-CSF, TNF- a , Flt-3 ligand, and IL-4, the blasts from the patients with AML M4 and M5a expressed CD 11c, CD80, CD83, CD86. These findings suggested that the leukemia cells of some AML subtypes can differentiate into DCs and might present leukemia-specific antigens directly to T lymphocytes.(2) Expression of cytokine-associated genes in DCs: The expression of cytokine-associated genes in DCs derived from umbilical cord blood (UCB) and adult peripheral blood (APB) was compared. The expression of the Th1 response-related genes and chemokine genes was significantly lower in UCB-DCs than in APB-DC in both maturation states. Calgranulins A and B, which are speculated to induce immune tolerance, showed higher expression in UCB-DCs. The expression of particular genes related to immune responses was significantly different between UCB-and APB-DCs, which may cause functional difference in DC-mediated immunity between newborns and adults.(3)The utility of recombinant Sendai virus(rSeV) for effective DC-mediated immunotherapy against childhood cancer; The ex vivo infection of immature DCs with rSeV induces their spontaneous maturation and activation. We tried to apply this result to the treatment for patients with childhood cancer to setablish a new powerful DC-mediated immunotherapy. Peripheral blood mononuclear cells were isolated from the children with cancer and were cultured in the presence 10% autologous serum, GM-CSF, IL-4 and TNF-α to generate DCs. When the generated DCs were infected with rSeV, the expression of CD80, CD83 and CD86 was markedly enhanced. These findings suggested that rSeV could be a powerful booster for DC-mediated cancer immunotherapy, which might improve the prognosis of children with cancer.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
治療成績に影響を及ぼす要因:II.宿主要因:薬理動態および薬理遺伝学日本小児血液学会編:小児白血病・リンパ腫の診療ガイドライン2007年版
影响治疗结果的因素: II. 宿主因素:药代动力学和药物遗传学 日本小儿血液学会编辑:儿童白血病和淋巴瘤临床实践指南 2007 年版
DOI:
--
发表时间:
2007
期刊:
影响因子:
--
作者:
[Matsuzaki, A, 松崎 彰信]
通讯作者:
松崎 彰信
Treatment results of relapsed childhood ALL: A report from the Kyushu-Yamaguchi Children's Cancer Study Group
儿童复发性 ALL 的治疗结果:九州山口儿童癌症研究小组的报告
DOI:
--
发表时间:
2006
期刊:
影响因子:
--
作者:
[Suminoe, A, Matsuzaki, A, Hattori, H, Koga, Y, Hara, T, Matsuzaki A]
通讯作者:
Matsuzaki A
初発時に急性白血病様の骨髄像を呈した原発不明胞巣型横紋筋肉腫
原发性未知囊肿的横纹肌肉瘤,初次发病时具有急性白血病样骨髓外观
DOI:
--
发表时间:
2007
期刊:
臨床血液 48
影响因子:
--
作者:
[山口 敢, 査賀 友紀, 住江 愛王, 齋藤 祐介, 松崎 彰信, 神野 俊介, 瀧本 智仁, 須田 正洋, 小田 義直, 武藤 敏孝, 高月 浩, 原寿 郎]
通讯作者:
原寿 郎
Expression and production of aberrant PAX5 with deletion of exon 8 in B-lineage acute lymphoblastic leukaemia of children.
儿童 B 系急性淋巴细胞白血病中外显子 8 缺失的异常 PAX5 的表达和产生。
DOI:
--
发表时间:
2006
期刊:
Br. J. Haematol. 136(2)
影响因子:
--
作者:
[Sakane Y, Mizutani S. et al.]
通讯作者:
Mizutani S. et al.
Long-term use of peripherally inserted central venous catheters (PICCs) for cancer chemotherapy in children
长期使用经外周静脉置入中心静脉导管(PICC)进行儿童癌症化疗
DOI:
--
发表时间:
2006
期刊:
Supportive Care in Cancer 14
影响因子:
--
作者:
[Matsuzaki A, Suminoe A, Koea Y, Hatano M, Hattori S, Hara T]
通讯作者:
Hara T
共 22 条
Application of dendritic cells and neutrophil-derived TRAIL to cancer cell therapy in children
-
批准号:16591039
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.37万
-
财政年份:2004
-
负责人:MATSUZAKI Akinobu
-
依托单位:
Establishment of cancer immunotherapy with autologous dendritic cells and tumor-specific antigens in children with refractory malignant tumors
-
批准号:13670815
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$1.98万
-
财政年份:2001
-
负责人:MATSUZAKI Akinobu
-
依托单位:
海外基金